Alison R Novak1, Mary E Bradley1, Tyree H Kiser1, Scott W Mueller1. 1. Department of Clinical Pharmacy, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences, 12850 East Montview Boulevard, Mail Stop C238, Aurora, CO 80045, USA.
Abstract
PURPOSE OF REVIEW: This review summarizes current treatment options for echinocandin-resistant Candida spp. (ERC) and azole-resistant Aspergillus fumigatus (ARAF), emphasizing recent in vitro/in vivo data, clinical reports, and consensus statements. RECENT FINDINGS: Advances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant on amphotericin products. Although novel antifungals may provide breakthroughs in the treatment of resistant fungi, these agents are not yet available. Early identification and appropriate treatment remain a paramount, albeit elusive, task. SUMMARY: When either ERC or ARAF are suspected or proven, amphotericin products remain the cornerstone of initial therapy. For ERC, azoles are de-escalation options for susceptible isolates in stable patients to avoid amphotericin toxicities. Although combination echinocandin with high-dose salvage posaconazole or isavuconazole may be attempted in ARAF, it requires careful consideration following patient stabilization. Future research defining optimal therapies and early identification of ERC and ARAF is of extreme importance.
PURPOSE OF REVIEW: This review summarizes current treatment options for echinocandin-resistant Candida spp. (ERC) and azole-resistant Aspergillus fumigatus (ARAF), emphasizing recent in vitro/in vivo data, clinical reports, and consensus statements. RECENT FINDINGS: Advances in ERC and ARAF treatment are limited to specific antifungal combinations and dose optimization but remain reliant on amphotericin products. Although novel antifungals may provide breakthroughs in the treatment of resistant fungi, these agents are not yet available. Early identification and appropriate treatment remain a paramount, albeit elusive, task. SUMMARY: When either ERC or ARAF are suspected or proven, amphotericin products remain the cornerstone of initial therapy. For ERC, azoles are de-escalation options for susceptible isolates in stable patients to avoid amphotericin toxicities. Although combination echinocandin with high-dose salvage posaconazole or isavuconazole may be attempted in ARAF, it requires careful consideration following patient stabilization. Future research defining optimal therapies and early identification of ERC and ARAF is of extreme importance.
Authors: Barbara D Alexander; Melissa D Johnson; Christopher D Pfeiffer; Cristina Jiménez-Ortigosa; Jelena Catania; Rachel Booker; Mariana Castanheira; Shawn A Messer; David S Perlin; Michael A Pfaller Journal: Clin Infect Dis Date: 2013-03-13 Impact factor: 9.079
Authors: Cau D Pham; Naureen Iqbal; Carol B Bolden; Randall J Kuykendall; Lee H Harrison; Monica M Farley; William Schaffner; Zintars G Beldavs; Tom M Chiller; Benjamin J Park; Angela A Cleveland; Shawn R Lockhart Journal: Antimicrob Agents Chemother Date: 2014-06-02 Impact factor: 5.191
Authors: Adam R Jeans; Susan J Howard; Zaid Al-Nakeeb; Joanne Goodwin; Lea Gregson; Peter A Warn; William W Hope Journal: Antimicrob Agents Chemother Date: 2012-07-23 Impact factor: 5.191
Authors: Jan W M van der Linden; Eveline Snelders; Greetje A Kampinga; Bart J A Rijnders; Eva Mattsson; Yvette J Debets-Ossenkopp; Ed J Kuijper; Frank H Van Tiel; Willem J G Melchers; Paul E Verweij Journal: Emerg Infect Dis Date: 2011-10 Impact factor: 6.883
Authors: Michael A Pfaller; Daniel J Diekema; John D Turnidge; Mariana Castanheira; Ronald N Jones Journal: Open Forum Infect Dis Date: 2019-03-15 Impact factor: 3.835
Authors: Elena De Carolis; Federica Marchionni; Marilisa La Rosa; Jacques F Meis; Anuradha Chowdhary; Brunella Posteraro; Maurizio Sanguinetti Journal: Front Cell Infect Microbiol Date: 2021-03-16 Impact factor: 5.293